Back to search

Article

The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided Strategies

2026-08-10

Abstract excerpt

<h4>Background: </h4> /Objectives: Perioperative chemoimmunotherapy has become an important curative-intent strategy for selected patients with resectable non-small cell lung cancer (NSCLC). However, most pivotal trials evaluate neoadjuvant therapy, surgery, and postoperative immune checkpoint inhibitor (ICI) treatment as an integrated regimen. Whether continued postoperative immunotherapy provides independent inc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d7dfe833-b3d0-5b85-a38e-682225cbe492
DOI
10.20944/preprints202608.0640.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided StrategiesDOI 10.20944/preprints202608.0640.v1
Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.Semantic proximity
Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapySemantic proximity
Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.Semantic proximity
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity
Early radiologic response after two cycles of neoadjuvant chemoimmunotherapy and pathologic outcomes in resectable non-small cell lung cancer: A multicenter retrospective studySemantic proximity
Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.Semantic proximity
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)Semantic proximity
Targeted Therapy in Early Stage Non-small Cell Lung Cancer.Semantic proximity
Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancerSemantic proximity
Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.Semantic proximity
Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?Semantic proximity
Select a neighboring publication to make it the new centre.